Comparative Pharmacology
Head-to-head clinical analysis: SUMYCIN versus TETRACHEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUMYCIN versus TETRACHEL.
SUMYCIN vs TETRACHEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
None Documented
None Documented
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic